Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aminophylline for CI-AKI Prevention in STEMI Patients
NCT01594489Phase 4Completed
- Sponsor
- Ospedale Misericordia e Dolce
- Start
- Jan 2009
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aminophylline in acute kidney injury (AKI), sponsored by Ospedale Misericordia e Dolce. Primary endpoint: Incidence of Contrast-Induced Acute Kidney Injury at 3 days. Started Jan 2009; status: completed.
02
Drugs
aminophylline
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT01594489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01594489.